Sanford C. Bernstein set a €108.00 ($125.58) price objective on Merck KGaA (FRA:MRK) in a research report released on Monday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
Several other equities analysts also recently issued reports on the stock. JPMorgan Chase & Co. set a €100.00 ($116.28) price objective on shares of Merck KGaA and gave the company a neutral rating in a report on Friday, April 12th. Warburg Research set a €103.00 ($119.77) price objective on shares of Merck KGaA and gave the company a neutral rating in a report on Tuesday, April 9th. UBS Group set a €108.00 ($125.58) price objective on shares of Merck KGaA and gave the company a neutral rating in a report on Tuesday, April 9th. Barclays set a €82.00 ($95.35) price objective on shares of Merck KGaA and gave the company a sell rating in a report on Monday, April 8th. Finally, DZ Bank reiterated a neutral rating on shares of Merck KGaA in a research report on Tuesday, April 2nd. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of €101.15 ($117.62).
MRK opened at €94.92 ($110.37) on Monday. Merck KGaA has a 52-week low of €76.60 ($89.07) and a 52-week high of €115.00 ($133.72).
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Article: Commodities
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.